- Home
- CTO vs KMDA Comparison
CTO vs KMDA Comparison
Compare CTO & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | KMDA |
|---|---|---|
| Founded | 1902 | 1990 |
| Country | United States | Israel |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 501.8M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CTO | KMDA |
|---|---|---|
| Price | $18.48 | $8.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $21.50 | $14.00 |
| AVG Volume (30 Days) | ★ 224.0K | 76.5K |
| Earning Date | 04-28-2026 | 03-11-2026 |
| Dividend Yield | ★ 8.24% | 3.10% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | $13.94 |
| Revenue Next Year | $2.76 | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $5.54 |
| 52 Week High | $20.25 | $9.35 |
Technical Indicators
Market Signals| Indicator | CTO | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 44.83 | 45.43 |
| Support Level | $17.14 | $6.62 |
| Resistance Level | $18.55 | $8.88 |
| Average True Range (ATR) | 0.35 | 0.22 |
| MACD | -0.08 | -0.07 |
| Stochastic Oscillator | 40.17 | 32.87 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.